Luliconazole

Luliconazole (NND 502)?is a topical antifungal imidazole antibiotic with broad-spectrum and potent antifungal activity. Luliconazole can be used for the research of skin infection, including?dermatophytosis, tinea corporis, tinea pedis?et al^[1]. In Vitro: The MICs of LLCZ against the organism measured by a standardized microdilution method using RPMI 1640 medium, were 0.002 μg/ml for?T. mentagrophytes?TIMM1189 and 0.002 μg/ml for TIMM2789^[1].
The minimum inhibitory concentrations (MIC) of luliconazole against Trichophyton spp. (T. rubrum, T. mentagrophytes and T. tonsurans) and Candida albicans are measured by the standardized broth microdilution method^[1].
Luliconazole demonstrates great potency against Trichophyton spp. (MIC range: 0.00012-0.002 μg/ml) than the reference agents, with T. rubrum being the most susceptible to it (MIC range: 0.00012-0.00024 μg/ml). Luliconazole is against T. mentagrophytes with MIC values ranging 0.00012-0.002 μg/ml. Luliconazole is also highly active against Candida albicans (MIC range: 0.031-0.13 μg/ml). Further, the MIC of luliconazole against Malassezia restricta is very low (MIC range: 0.004-0.016 μg/ml)^[1].
In Vivo: Luliconazole (subcutaneous injection; 1, 5 and 25 mg/kg/day) is administered from the beginning of organogenesis (gestation day 7) through the end of lactation (lactation day 20). Luliconazole at 25 mg/kg presents maternal toxicity and embryofetal toxicity (increased prenatal pup mortality, reduced live litter sizes and increased postnatal pup mortality). Luliconazole at 5 mg/kg exhibits no embryofetal toxicity. Additionally, at 25 mg/kg/day has no treatment effects on postnatal development in rats^[2].
Luliconazole (appliance on skin; 0.02%-1%; 7-14 days) has dose-dependent therapeutic efficacy on skin, it exerts efficacy its even at a concentration of 0.02%, and its efficacy at 0.1% is equal to that of 1% bifonazole creama tinea corporis model?(4- and 8-day treatment) and the tinea pedis model (7- and 14-day treatment)^[3].